fasudil has been researched along with Pulmonary Arterial Remodeling in 4 studies
fasudil: intracellular calcium antagonist; structure in first source
fasudil : An isoquinoline substituted by a (1,4-diazepan-1-yl)sulfonyl group at position 5. It is a Rho-kinase inhibitor and its hydrochloride hydrate form is approved for the treatment of cerebral vasospasm and cerebral ischemia.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this study was to investigate the effects of Rho kinase inhibitor-Fasudil on hypoxic pulmonary hypertension (HPH) and pulmonary vascular remodeling in rats." | 7.80 | Effects of fasudil on hypoxic pulmonary hypertension and pulmonary vascular remodeling in rats. ( Li, J; Sun, XZ; Tian, XY; Wang, DW, 2014) |
| "The aim of this study was to investigate the effects of Rho kinase inhibitor-Fasudil on hypoxic pulmonary hypertension (HPH) and pulmonary vascular remodeling in rats." | 3.80 | Effects of fasudil on hypoxic pulmonary hypertension and pulmonary vascular remodeling in rats. ( Li, J; Sun, XZ; Tian, XY; Wang, DW, 2014) |
| "Fasudil‑treated mice developed a significantly smaller intima‑media thickness compared with the untreated mice." | 1.42 | Fasudil, a Rho‑kinase inhibitor, prevents intima‑media thickening in a partially ligated carotid artery mouse model: Effects of fasudil in flow‑induced vascular remodeling. ( Gao, F; Li, Q; Li, W; Li, Y; Shen, C; Zhang, T; Zhang, X, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Li, C | 1 |
| Liu, PP | 1 |
| Tang, DD | 1 |
| Song, R | 1 |
| Zhang, YQ | 1 |
| Lei, S | 1 |
| Wu, SJ | 1 |
| Zhuang, R | 1 |
| Wu, J | 1 |
| Lin, F | 1 |
| Han, L | 1 |
| Liang, X | 1 |
| Meng, Q | 1 |
| Jiang, Y | 1 |
| Wang, Z | 1 |
| Yue, A | 1 |
| Gu, Y | 1 |
| Fan, H | 1 |
| Zhou, X | 1 |
| Liu, Z | 1 |
| Sun, XZ | 1 |
| Tian, XY | 1 |
| Wang, DW | 1 |
| Li, J | 1 |
| Zhang, X | 2 |
| Zhang, T | 1 |
| Gao, F | 1 |
| Li, Q | 1 |
| Shen, C | 1 |
| Li, Y | 1 |
| Li, W | 1 |
4 other studies available for fasudil and Pulmonary Arterial Remodeling
| Article | Year |
|---|---|
Targeting the RhoA-ROCK pathway to regulate T-cell homeostasis in hypoxia-induced pulmonary arterial hypertension.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Hypertension, Pulmonary; Hypoxia; Interleuki | 2018 |
Fasudil preserves lung endothelial function and reduces pulmonary vascular remodeling in a rat model of end‑stage pulmonary hypertension with left heart disease.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Cardiomegaly; Cell Line; Heart Diseases; Hum | 2018 |
Effects of fasudil on hypoxic pulmonary hypertension and pulmonary vascular remodeling in rats.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Arterioles; Blood Pressure; Carotid Arteries | 2014 |
Fasudil, a Rho‑kinase inhibitor, prevents intima‑media thickening in a partially ligated carotid artery mouse model: Effects of fasudil in flow‑induced vascular remodeling.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Carotid Arteries; Carotid Intima-Media Thick | 2015 |